Abstract: Most patients undergoing dialysis are required to take many phosphate binder pills to control hyperphosphatemia. Phosphate binders prescribed in Japan are classified into two types: metal-based binders (Ca carbonate, lanthanum carbonate, ferric citrate hydrate, and sucroferric oxyhydroxide) and chemically synthesized polymers (sevelamer hydrochloride and bixalomer). The raw materials of metal-based phosphate binders are natural ores; thus, such binders may contain several other metallic elements. We measured the elemental contents in six metalbased phosphate binders using an inductively coupled plasma mass -spectrometry (ICP-MS) method. As a result, despite being in small amounts, ore-derived phosphate binders contained various elements besides their active ingredient metals: Na, Mg, P, Mn, Fe, Sr, Y, Ba, La, Nd, and Pb in three Ca-based products; Mg, P, Se, Ce, and Gd in one La-based product; and Na, Mg, Al, P, Ca, Ti, Cr, Mn, Co, Ni, Ge, Ba, and La in two Fe-based products. These elements are considered to have originated from pharmaceutical bulk and from pharmaceutical additives. It is unlikely these elements are immediately harmful to patients. However, it should be emphasized that patients undergoing dialysis do not have a urinary excretion route and are administered many phosphate binder pills every day over a long period of time. In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores.
Hyperphosphatemia is a widely recognized risk factor for mortality and cardiovascular disease in patients undergoing dialysis (1, 2) . To control hyperphosphatemia, pharmacological treatment with oral phosphate binders is necessary in addition to dietary phosphate restriction (3) (4) (5) . Although it remains unclear whether phosphate binder treatment can reduce mortality (6) (7) (8) , a large cohort study in 12 countries has reported that 88% of dialysis patients were prescribed phosphate binders (6) . Furthermore, dialysis patients are required to take many phosphate binder pills every day over a long period of time (9) .
Currently, there are six types of phosphate binders approved for dialysis patients in Japan. These phosphate binders are roughly classified into two types: metal-based binders [calcium (Ca) carbonate, lanthanum (La) carbonate, ferric citrate hydrate, and sucroferric oxyhydroxide] and chemically synthesized polymers (sevelamer hydrochloride and bixalomer). Of these, the raw materials of metal-based phosphate binders are natural ores: Ca from lime stone, La from monazite ore, and iron (Fe) from iron ore. Therefore, irrespective of the methods used to purify or chemically refine these ores, metal-based phosphate binders may contain several elements other than their active ingredient metals (Ca, La, and Fe, for each). In the present study, we determined the type and quantity of elements present in six metal-based phosphate binders using inductively coupled plasma-mass spectrometry (ICP-MS).
MATERIALS AND METHODS
In total, six prescription-only phosphate binder products (three Ca carbonate products, La carbonate product, and two Fe-based products) produced by different pharmaceutical manufactures were measured: Precipitated Ca Carbonate Tablet SANWA 500 mg (A) (Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan); Caltan-OD Tablets 500 mg (B) (Mylan Inc., Osaka, Japan); CARTAR-ETIN 500 mg (C) (Teva Takeda Pharma Ltd., Nagoya, Japan); Fosrenol Chewable Tablets 500 mg (D) (Bayer Yakuhin, Ltd., Osaka, Japan); sucroferric oxyhydroxide, P-TOL Chewable Tab. 500 mg (E) (Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan); and ferric citrate hydrate, Riona Tab. 250 mg (F) (Japan Tobacco Inc., Tokyo, Japan).
All the tablets were crushed and ground into powder. A part of the test material was weighed and treated with nitric acid and hydrochloric acid, heated at 60 C for 1 h, and then pressure filtrated with a membrane filter (0.45 μm). Elemental contents were measured using ICP-MS (7700x, Agilent Technologies Inc., Santa Clara, CA, USA) at a contract research organization (A-kit Inc., Ogaki, Japan). The first step included the measurement of 67 elements (Li, Be, B, Na, Mg, Al, Si, P, K, Ca, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, As, Se, Rb, Sr, Y, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, In, Sn, Sb, Te, Cs, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Ir, Pt, Au, Tl, Pb, Bi, Th, and U) in all the six products by qualitative analysis using a calibration curve with one point. All elements over or around the limit of quantitation (LOQ) were selected. The second step included the measurement of 30 elements in three Ca carbonate products (A, B, C), 14 elements in a La carbonate product (D), and 18 elements in two Fe-based products (E, F) by quantitative analysis using a calibration curve with multiple points. Each sample was measured in triplicate and repeated with another aliquot. The measured elements and LOQ of each element from the quantitative analysis are listed in Table 1 .
RESULTS
All three Ca carbonate products (A, B, C) commonly contained Mg, Mn, Fe, Sr, Y, Ba, La, and Nd, in addition to Ca, the active ingredient metal (Table 1 ). In addition, both products A and B contained Na. Furthermore, P and Pb were detected in products A and C, respectively, although they were around LOQ. The La carbonate product (D) contained Mg, P, Se, Ce, and Gd, in addition to La. Both Fe-based products (E, F) commonly contained Na, Mg, Ca, Cr, Ge, and La, in addition to Fe. Furthermore, Al, Ti, Mn, Co, Ni, and Ba were detected in product F.
DISCUSSION Presumed origin of elements
All Ca carbonate products commonly contained a relatively moderate amount of Mg, in addition to a large amount of Ca. We considered two potential origins of Mg. First, pharmaceutical grade precipitated Ca carbonate is produced through a recarbonization process: limestone (calcite, aragonite; CaCO 3 ) is calcinated, slaked with water, purified, and then recarbonized with carbon dioxide. Originally, limestone is a sedimentary rock composed of skeletons of ancient marine organisms that have been partly metamorphosed into dolostone (dolomite; CaMg[CO 3 ] 2 ) over the ages. Therefore, most Mg detected in all three Ca carbonate products may have originated from pharmaceutical bulk. In addition to Mg, dolomite contains Fe, Mn, Zn, and other trace elements, because these elements can substitute for Mg (10) . Thus, these metallic elements detected in Ca carbonate products may also have originated from pharmaceutical bulk. Second, it is clear that a separate origin of Mg in products A and C is from Mg stearate, which is added as a pharmaceutical excipient; this component is mentioned on the package inserts of drugs but its actual amount is not revealed. Because Mg stearate is not added to product B according to its package insert, it is reasonable that the Mg content of products A and C was higher than that of product B. Similarly, most Na content may have originated from pharmaceutical excipients: saccharin Na in product A and Na stearyl fumarate in product B, whereas Na was not detected as mentioned no pharmaceutical excipients containing Na in product C.
The raw material for the La carbonate product is monazite ore. There are four types of monazite ore depending on the relative elemental composition: (La, Ce, Nd)PO 4 , (Ce, La, Nd, Th)PO 4 , (Nd, La, Ce)PO 4 , and (Sm, Gd, Ce, Th)PO 4 ; the elements in parentheses are in the order of their relative proportions. Therefore, P, Ce, and Gd detected in product D may have originated from pharmaceutical bulk. It is interesting that other lanthanides (Pr, Nd, and Sm), actinides (Th and U), and Y, which are known to be present in monazite (11, 12) , were not detected. In addition, the origin of Se remains unclear. Furthermore, a certain amount of Mg detected in product D is considered to be originated from Mg stearate added as a pharmaceutical excipient according to its package insert.
The two different iron-based phosphate binder products (E, F) commonly contained several elements (Na, Mg, Ca, Cr, Ge, and La), in addition to Fe. 2 ] added as pharmaceutical excipients. Similarly, parts of Mg, Ca, and Ti in product F are derived from talc, Ca stearate, and titanium oxide (TiO 2 ), respectively. In contrast, the reason for the absence of Si in products E and F remains unclear; however, the amount of added talc may be extremely small. In addition, some elements detected in only one product may partly be because of differences in the production areas of iron ores around the world. Furthermore, lot-to-lot variation should also be considered.
In the present study, aluminum (Al)-based phosphate binder products were excluded from measurements because they have been contraindicated in dialysis patients, owing to neuronal, hematological, and bone toxicities (3) in Japan since 
Safety
Humans tend to subconsciously believe that pharmaceuticals should be extremely pure because they are medicines prescribed at hospitals and not market food. Almost all nephrologists prescribe phosphate binders believing that they contain only the active ingredient, and patients believe the same. In the present study, it was a natural result that the active ingredient metals (Ca, La, and Fe in Ca carbonate, La carbonate, and Fe-based products, respectively) were detected at much higher concentrations than LOQ. At the same time, a total of 21 different elements in six products were detected over LOQ. Of these, nine elements (Na, Mg, P, Ca, Cr, Mn, Fe, Co, and Se) are essential for humans. The highest percentage of these metals in active ingredient metals was Na in product E; however, it (Na) comprised only 2.5% of Fe. Thus, ingesting these amounts from phosphate binders is almost negligible. Of note, some phosphate binder products themselves contain P, although the P content in phosphate binders was much less than that in other drugs most commonly prescribed to dialysis patients (13) . Similarly, the Mn content in phosphate binders was fairly small when compared with that in a health supplement (chlorella extract; 139 μg/g), which has been reported to cause secondary parkinsonism by long-term and high-dose ingestion in a dialysis patient (14) .
Relatively moderate amounts of Mg were present in all three Ca carbonate products. In our dialysis center, serum Mg levels in 324 dialysis patients who were prescribed Ca carbonate product (A) were 2.5 (2.3-2.7) mg/dL [median (Q1-Q3)], whereas those in 181 dialysis patients not receiving any Ca carbonate products were 2.3 (2.1-2.5) mg/dL (P < 0.001, Mann-Whitney U-test) (15) . It has been reported that the all-cause mortality reaches a nadir at serum Mg levels ranging from 2.5 to 3.0 mg/dL in two large cohort studies with Japanese dialysis patients (16, 17) . Thus, it may be considered that Mg present in Ca carbonate products leads to benefits rather than health concerns in this patient population. Indeed, this consideration may be justified by the findings of two studies that demonstrate that Mg-containing phosphate binder (Ca acetate/Mg carbonate) reduces vascular and cardiac calcification in rats with chronic kidney disease (18) and dialysis patients (19) . Similarly, a small amount of Sr detected in Ca carbonate products might be beneficial for dialysis patients with metabolic bone disease. Sr ranelate itself has been used as a drug for the treatment of osteoporosis (20) , and the daily estimated Sr intake volume from Ca carbonate products (see the Pb section below) is much less than the clinical dose of Sr ranelate (2 g/day).
One of the three Ca carbonate products (C) contained a trace amount of Pb, which is notorious for cardiovascular, hematological, immune, reproductive, and neurological developmental toxicities (21) . Pb may have originated from pharmaceutical bulk despite being chemically refined because ancient marine calcareous deposits inevitably contain some Pb (22) . Similarly, it has been reported that many Ca supplement formulations contain measurable amounts of Pb, whereas prescription-only Ca acetate formulation as a phosphate binder does not (23) . The Japanese Society for Dialysis Therapy (JSDT) clinical practice guidelines recommend an upper dose limit of Ca carbonate products of 3 g/day to avoid cardiovascular calcification (24) . Therefore, daily intake of 3.3 μg of Pb (when taking 3 g of product C) is nearer the lower value of the national Pb dietary exposure estimates for adults (21) . However, long-term use by dialysis patients may be of concern because urine and feces are the major routes of Pb excretion (21) . In contrast, the fact that Pb is present in the Ca carbonate product appears to be fortuitous because intestinal Pb absorption declines in the presence of Ca, and as a result, blood Pb levels are inversely correlated with dietary Ca intake (22, 25, 26) . Therefore, nephrologists should refrain from prescribing large doses of Ca carbonate, whether it contains Pb or not, so as not to promote cardiovascular calcification, which would naturally lead to reduced Pb exposure in dialysis patients. As a matter of course, the influences of other trace elements detected in the present study should not be ignored and should be addressed in future studies.
CONCLUSION
Ore-derived phosphate binders contained various elements besides their active ingredient metals. These elemental contents were very small in quantity, and it is unlikely that they will have immediate disadvantages to patients. However, dialysis patients do not have a urinary excretion route and are administered large amounts of phosphate binder products every day over a long period of time. In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores.
